Detalhe da pesquisa
1.
A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy.
Neurobiol Dis
; 159: 105507, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34509608
2.
Functionalization of the TMEM175 p.M393T variant as a risk factor for Parkinson disease.
Hum Mol Genet
; 28(19): 3244-3254, 2019 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31261387
3.
TMEM175 deficiency impairs lysosomal and mitochondrial function and increases α-synuclein aggregation.
Proc Natl Acad Sci U S A
; 114(9): 2389-2394, 2017 02 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-28193887
4.
Box C/D small nucleolar RNA (snoRNA) U60 regulates intracellular cholesterol trafficking.
J Biol Chem
; 288(50): 35703-13, 2013 Dec 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-24174535
5.
Fluorinated Isoindolinone-Based Glucosylceramide Synthase Inhibitors with Low Human Dose Projections.
ACS Med Chem Lett
; 15(1): 123-131, 2024 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38229758
6.
Pyrazole Ureas as Low Dose, CNS Penetrant Glucosylceramide Synthase Inhibitors for the Treatment of Parkinson's Disease.
ACS Med Chem Lett
; 14(2): 146-155, 2023 Feb 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36793422
7.
Intracranial administration of alpha-synuclein fibrils in A30P-synuclein transgenic mice causes robust synucleinopathy and microglial induction.
Neurobiol Aging
; 106: 12-25, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34225000
8.
snoRNA U17 regulates cellular cholesterol trafficking.
Cell Metab
; 21(6): 855-67, 2015 Jun 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-25980348